Pharmacogenomics in clinical trials: an overview
Open Access
- 20 October 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1247088
Abstract
With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be considered for improving our knowledge about the effectiveness and safety of new drugs. A search of available clinical trials containing pharmacogenetic and PGx information was conducted on ClinicalTrials.gov. The results show there has been an increase in the number of trials containing PGx information since the 2000 s, with particular relevance in the areas of Oncology (28.43%) and Mental Health (10.66%). Most of the clinical trials focus on treatment as their primary purpose. In those clinical trials entries where the specific genes considered for study are detailed, the most frequently explored genes are CYP2D6 (especially in Mental Health and Pain), CYP2C9 (in Hematology), CYP2C19 (in Cardiology and Mental Health) and ABCB1 and CYP3A5 (particularly prominent in Transplantation and Cardiology), among others. Researchers and clinicans should be trained in pharmacogenetics and PGx in order to be able to make a proper interpretation of this data, contributing to better prescribing decisions and an improvement in patients’ care, which would lead to the performance of PM.Keywords
This publication has 45 references indexed in Scilit:
- Primary care physicians' knowledge of and experience with pharmacogenetic testingClinical Genetics, 2012
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT ProjectClinical Pharmacology & Therapeutics, 2012
- Attitudes of Health Care Professionals Toward Pharmacogenetic TestingMolecular Diagnosis & Therapy, 2011
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- Pharmacogenomics: The Right Drug to the Right PersonJournal of Clinical Medicine Research, 2009
- Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug ReactionsNew England Journal of Medicine, 2008
- Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of EducationThe Pharmacogenomics Journal, 2005
- Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics ReportJournal of Medical Ethics, 2005
- Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?Clinical Genetics, 1999
- DRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICSJAMA, 1957